Abstract Search

10.13. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes

SA Brown , BP Kovatchev , D Raghinaru , JW Lum , BA Buckingham , YC Kudva , LM Laffel , CJ Levy , JE Pinsker , RP Wadwa , E Dassau , FJ 3rd Doyle , SM Anderson , MM Church , V Dadlani , L Ekhlaspour , GP Forlenza , E Isganaitis , DW Lam , C Kollman , RW Beck , iDCL Trial Research Group.

To read the full abstract: N Engl J Med. 2019 Oct 31;381(18):17071717. doi: 10.1056/NEJMoa1907863. PMID: 31618560Despite advances in diabetes care, attaining good glycemic outcomes in patients with type 1 diabetes (T1DM) remains challenging and often is not achieved. For example, the targets set by the American Diabetes Association are met in only a minority of patients. It is hoped th...

0 shares

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 717 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...

0 shares

ESPE Yearbook of Paediatric Endocrinology

10.13. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

BiosciAbstracts